|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, December 10, 2016 ) The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects.
For more information about this report at http://www.reportsweb.com/bone-marrow-transplant-rejection-pipeline-review-h2-2016
Report Scope:
- The report provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection
- The report reviews pipeline therapeutics for Bone Marrow Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Bone Marrow Transplant Rejection therapeutics and enlists all their major and minor projects
- The report assesses Bone Marrow Transplant Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001412649/sample
Reasons to buy:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplant Rejection
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Companies profiles
AbbVie Inc
AbGenomics International, Inc.
Actelion Ltd
Alexion Pharmaceuticals Inc
Amunix Operating Inc.
Apceth GmbH & Co. KG
arGEN-X BV
Athersys, Inc.
Bellicum Pharmaceuticals, Inc.
Bio-Cancer Treatment International Limited
Biogen Inc
Boryung Pharmaceutical Co., Ltd.
Bristol-Myers Squibb Company
Cantex Pharmaceuticals, Inc.
Capricor Therapeutics, Inc.
Cell Source, Inc.
Cell2B S.A.
CellECT Bio, Inc.
Cleveland BioLabs, Inc.
Compugen Ltd.
Cynata Therapeutics Limited
Cytodyn Inc.
Dompe Farmaceutici S.p.A.
Dr. Falk Pharma GmbH
Escape Therapeutics, Inc.
F. Hoffmann-La Roche Ltd.
Fate Therapeutics, Inc.
Generon (Shanghai) Corporation Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Idera Pharmaceuticals, Inc.
ImmuNext, Inc.
Immunomedics, Inc.
Incyte Corporation
Kadmon Corporation, LLC
Kamada Ltd.
Kiadis Pharma N.V.
Kymab Limited
Kyorin Pharmaceutical Co., Ltd.
MacroGenics, Inc.
Mallinckrodt Plc
Medsenic
Mesoblast Limited
Millennium Pharmaceuticals Inc
Neopharm Ltd.
Nohla Therapeutics Inc.
Novartis AG
OncoImmune, Inc.
OSE Immunotherapeutics
Pharmicell Co., Ltd.
Pluristem Therapeutics Inc.
REGiMMUNE Corporation
Rigel Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc.
Seattle Genetics, Inc.
Seres Therapeutics, Inc.
Sigmoid Pharma Limited
Spherium Biomed S.L.
Taiga Biotechnologies, Inc.
Takeda Pharmaceutical Company Limited
Targazyme, Inc.
Therapix Biosciences Ltd
Tobira Therapeutics, Inc.
Vault Pharma Inc.
Xenikos B.V.
ZIOPHARM Oncology, Inc.
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001412649/discount
List of Figures:
Number of Products under Development for Bone Marrow Transplant Rejection, H2 2016 20
Number of Products under Development for Bone Marrow Transplant Rejection - Comparative Analysis, H2 2016 21
Number of Products under Development by Companies, H2 2016 22
Number of Products under Investigation by Universities/Institutes, H2 2016 27
Comparative Analysis by Clinical Stage Development, H2 2016 30
Comparative Analysis by Early Stage Products, H2 2016 31
Assessment by Monotherapy Products, H2 2016 107
Number of Products by Top 10 Targets, H2 2016 109
Number of Products by Stage and Top 10 Targets, H2 2016 109
Number of Products by Top 10 Mechanism of Actions, H2 2016 113
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 113
Number of Products by Top 10 Routes of Administration, H2 2016 117
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 117
Number of Products by Top 10 Molecule Types, H2 2016 119
Number of Products by Stage and Top 10 Molecule Types, H2 2016 119 Number of Products under Development for Bone Marrow Transplant Rejection, H2 2016 20
Number of Products under Development for Bone Marrow Transplant Rejection - Comparative Analysis, H2 2016 21
Number of Products under Development by Companies, H2 2016 22
Number of Products under Investigation by Universities/Institutes, H2 2016 27
Comparative Analysis by Clinical Stage Development, H2 2016 30
Comparative Analysis by Early Stage Products, H2 2016 31
Assessment by Monotherapy Products, H2 2016 107
Number of Products by Top 10 Targets, H2 2016 109
Number of Products by Stage and Top 10 Targets, H2 2016 109
Number of Products by Top 10 Mechanism of Actions, H2 2016 113
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 113
Number of Products by Top 10 Routes of Administration, H2 2016 117
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 117
Number of Products by Top 10 Molecule Types, H2 2016 119
Number of Products by Stage and Top 10 Molecule Types, H2 2016 119
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
